Michael Schmidt Analyst PerformanceSenior Biotech Analyst at GuggenheimMichael Schmidt is a stock analyst at Guggenheim focused in the medical sector, covering 45 publicly traded companies. Over the past year, Michael Schmidt has issued 38 stock ratings, including buy and hold recommendations. While full access to Michael Schmidt's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Schmidt's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings143 Last 11 YearsBuy Recommendations87.94% 124 Buy RatingsCompanies Covered45 Unique Companies Ratings Distribution141RatingsDistribution of strong buy, buy, hold, and sell ratings by Michael Schmidt.RatingPercentageCount Strong Buy0.0%0 ratings Buy87.9%124 ratings Hold12.1%17 ratings Sell0.0%0 ratingsOut of 141 total stock ratings issued by Michael Schmidt at Guggenheim, the majority (87.9%) have been Buy recommendations, followed by 12.1% Hold.Best & Worst CallsBest Call0000.0%NBTXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DAREJun 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.8% of companies on NASDAQ44 companiesNYSE2.2% of companies on NYSE1 companyMichael Schmidt, an analyst at Guggenheim, currently covers 45 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical44 companies97.8%Energy1 company2.2%Michael Schmidt of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Energy companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE32 companies71.1%MED - DRUGS6 companies13.3%PHARMACEUTICAL PREPARATIONS3 companies6.7%BIOTECHNOLOGY2 companies4.4%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company2.2%SOLAR1 company2.2% About Michael SchmidtDr. Schmidt is a Senior Managing Director and Equity Research Analyst covering the Biotechnology sector based in Guggenheim’s Boston office. With over 17 years of Wall Street experience, Dr. Schmidt joined Guggenheim from Leerink Partners in 2018 where he was a Senior Biotechnology Research Analyst. Previously, he was a healthcare analyst and consultant at Susquehanna International Group’s private equity team in San Francisco and a research fellow at Harvard University. Dr. Schmidt earned his M.S. in Biology and Ph.D. in Biochemistry at the University of Stuttgart, Germany. Dr. Schmidt was named runner-up in the 2017 Institutional Investor All-America Research Survey, Biotechnology/Mid- & Small-Cap.Follow on LinkedIn Michael Schmidt's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsENGNenGene5/7/2026Downgrade$1.72Neutral$0.0000.00% ROIONCBeOne Medicines5/7/2026Boost Price Target$313.32$420.00Buy$0.0000.00% ROIRVMDRevolution Medicines5/7/2026Boost Price Target$151.07$205.00Buy$0.0000.00% ROIZNTLZentalis Pharmaceuticals4/10/2026Boost Price Target$4.42$10.00Buy$0.0000.00% ROINBTXNanobiotix4/2/2026Boost Price Target$30.91$36.00Buy$0.0000.00% ROIZNTLZentalis Pharmaceuticals3/27/2026Reiterated Rating$2.67$6.00Buy$0.0000.00% ROICMPXCompass Therapeutics3/24/2026Reiterated Rating$4.97$12.00Buy$0.0000.00% ROICTMXCytomX Therapeutics3/18/2026Boost Price Target$5.45$15.00Buy$0.0000.00% ROIGLUEMonte Rosa Therapeutics3/18/2026Lower Price Target$16.03$30.00Buy$0.0000.00% ROIERASErasca3/16/2026Boost Price Target$13.62$20.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CTMXCytomX Therapeutics3/9/2026Reiterated Rating$4.68$10.00Buy$0.0000.00% ROIXFORX4 Pharmaceuticals3/9/2026Initiated Coverage$3.76$12.00Buy$0.0000.00% ROITNGXTango Therapeutics3/6/2026Boost Price Target$16.80$20.00Buy$0.0000.00% ROIONCBeOne Medicines2/27/2026Boost Price Target$319.84$410.00Buy$0.0000.00% ROIGMABGenmab A/S2/23/2026Lower Price Target$29.17$40.00Buy$0.0000.00% ROITNGXTango Therapeutics2/6/2026Boost Price Target$12.50$18.00Buy$0.0000.00% ROINBTXNanobiotix2/6/2026Boost Price Target$21.66$26.00Buy$0.0000.00% ROICTMXCytomX Therapeutics1/20/2026Initiated Coverage$5.39$10.00Buy$0.0000.00% ROICTMXCytomX Therapeutics1/20/2026Initiated Coverage$5.37$10.00Buy$0.0000.00% ROIGLUEMonte Rosa Therapeutics1/8/2026Boost Price Target$23.38$34.00Buy$0.0000.00% ROIIMNMImmunome12/16/2025Boost Price Target$22.64$35.00Buy$0.0000.00% ROIADCTADC Therapeutics11/12/2025Reiterated Rating$3.97$10.00Buy$0.0000.00% ROIFHTXFoghorn Therapeutics11/7/2025Initiated Coverage$4.00$12.00Buy$0.0000.00% ROIINCYIncyte11/3/2025Upgrade$93.48$125.00Buy$0.0000.00% ROIGMABGenmab A/S9/23/2025Upgrade$28.60$43.00Buy$0.0000.00% ROIINCYIncyte9/19/2025Reiterated Rating$86.00Neutral$0.0000.00% ROIIMNMImmunome8/25/2025Reiterated Rating$10.49$25.00Buy$0.0000.00% ROIMRSNMersana Therapeutics8/14/2025Lower Price Target$6.96$30.00Buy$0.0000.00% ROIADCTADC Therapeutics8/13/2025Reiterated Rating$3.08$10.00Buy$0.0000.00% ROIORICOric Pharmaceuticals8/13/2025Reiterated Rating$10.01$18.00Buy$0.0000.00% ROICMPXCompass Therapeutics8/12/2025Boost Price Target$3.34$12.00Buy$0.0000.00% ROIONCBeOne Medicines8/7/2025Boost Price Target$296.33$365.00Buy$0.0000.00% ROIARVNArvinas8/7/2025Lower Price Target$6.19$15.00Buy$0.0000.00% ROITNGXTango Therapeutics8/6/2025Boost Price Target$6.35$10.00Buy$0.0000.00% ROICOGTCogent Biosciences7/8/2025Reiterated Rating$9.16$17.00Buy$0.0000.00% ROIRVMDRevolution Medicines6/25/2025Reiterated Rating$39.18$80.00Buy$0.0000.00% ROIADCTADC Therapeutics6/13/2025Reiterated Rating$3.77$10.00Buy$0.0000.00% ROIKYMRKymera Therapeutics6/3/2025Reiterated Rating$49.69$60.00Buy$0.0000.00% ROIURGNUrogen Pharma5/23/2025Lower Price Target$3.93$15.00Buy$0.0000.00% ROIMRSNMersana Therapeutics5/16/2025Reiterated Rating$8.20$125.00Buy$0.0000.00% ROIYour book is inside (Ad)The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.Download your copy now.EXELExelixis5/15/2025Set Price Target$45.40$45.00Buy$00.0000.00% ROIERASErasca5/14/2025Set Price Target$1.29$3.00Buy$00.0000.00% ROIKYMRKymera Therapeutics5/12/2025Reiterated Rating$31.92$52.00Buy$00.0000.00% ROIRVMDRevolution Medicines5/8/2025Lower Price Target$42.50$80.00Buy$000.0000.00% ROIONCBeOne Medicines5/8/2025Boost Price Target$233.78$350.00Buy$000.0000.00% ROIRLAYRelay Therapeutics5/7/2025Lower Price Target$3.03$10.00Buy$00.0000.00% ROISNDXSyndax Pharmaceuticals5/6/2025Reiterated Rating$12.16$32.00Buy$00.0000.00% ROIARVNArvinas5/2/2025Lower Price Target$7.00$16.00Buy$00.0000.00% ROISWTXSpringWorks Therapeutics4/28/2025Downgrade$46.18$47.00Neutral$0.0000.00% ROIONCBeOne Medicines4/16/2025Reiterated Rating$234.88Buy$000.0000.00% ROIONCBeOne Medicines4/10/2025Reiterated Rating$211.15$348.00Buy$000.0000.00% ROINBTXNanobiotix4/4/2025Lower Price Target$3.27$8.00Buy$00.0000.00% ROIADCTADC Therapeutics3/31/2025Lower Price Target$1.34$7.00Buy$0.0000.00% ROIMRUSMerus3/28/2025Reiterated Rating$44.63$109.00Buy$0.0000.00% ROIADAPAdaptimmune Therapeutics3/26/2025Lower Price Target$0.25$1.75Buy$0.0000.00% ROIIMNMImmunome3/20/2025Lower Price Target$8.47$25.00Buy$00.0000.00% ROIINCYIncyte3/18/2025Downgrade$62.01$92.00Neutral$00.0000.00% ROIMRUSMerus3/18/2025Reiterated Rating$46.94$109.00Buy$0.0000.00% ROIARVNArvinas3/13/2025Lower Price Target$8.52$32.00Buy$00.0000.00% ROILEGNLegend Biotech3/12/2025Reiterated Rating$37.63Neutral$00.0000.00% ROIAVBPArriVent BioPharma3/10/2025Initiated Coverage$21.87$45.00Buy$00.0000.00% ROIORICOric Pharmaceuticals2/26/2025Reiterated Rating$8.69Buy$00.0000.00% ROICMPXCompass Therapeutics2/24/2025Initiated Coverage$2.92$12.00Buy$0.0000.00% ROIEXELExelixis2/12/2025Reiterated Rating$35.11$42.00Buy$00.0000.00% ROIARVNArvinas2/12/2025Reiterated Rating$18.83$57.00Buy$00.0000.00% ROIMRUSMerus2/12/2025Reiterated Rating$40.02Buy$0.0000.00% ROIORICOric Pharmaceuticals2/10/2025Reiterated Rating$12.25Buy$00.0000.00% ROIIPSCCentury Therapeutics1/22/2025Reiterated Rating$0.90Buy$0.0000.00% ROIEXELExelixis1/22/2025Reiterated Rating$33.97Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWells Fargo & CompanyRoyal Bank Of CanadaJefferies Financial GroupThe Goldman Sachs GroupBMO Capital MarketsScotiabankNational Bank FinancialSanford C. BernsteinGuggenheimATB Cormark Capital MarketsTDOddo BhfCICC ResearchScotia Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
